The effects of adenosine and the nonmetabolizable adenosine analogue N6-(L-2-phenylisopropyl)adenosine (PTA) on glucose transport or metabolism were determined in purified myocardial sarcolemmal vesicles, isolated cardiocytes, and perfused hearts. Adenosine (100 ,uM) did not affect hexose transport in myocytes. Also, adenosine deaminase, added to metabolize adenosine to inosine, did not alter transport of hexose into myocytes regardless of whether or not insulin was present. In contrast, PIA effectively inhibited 3-0-methyl-D-glucose uptake in myocytes even during insulin stimulation. PTA inhibited D-glucose-specific transport in both rat and bovine cardiac sarcolemmal vesicles (Ki=26 ,uM at [D-glucose] =5 mM). However, insulin did not affect glucose transport in sarcolemmal vesicles, which implies that receptorcoupled processes probably are not intact in this preparation. Thus, inhibition of PIA may not be receptor mediated. Also, PIA inhibited binding of cytochalasin B to bovine cardiac sarcolemmal vesicles, which supports the idea that PTA inhibits glucose flux by binding to the glucose transporter. To determine if adenosine altered glucose metabolism rather than transport, we measured the rate of 3H20 production from metabolism of 
The effects of adenosine and the nonmetabolizable adenosine analogue N6-(L-2-phenylisopropyl)adenosine (PTA) on glucose transport or metabolism were determined in purified myocardial sarcolemmal vesicles, isolated cardiocytes, and perfused hearts. Adenosine (100 ,uM) did not affect hexose transport in myocytes. Also, adenosine deaminase, added to metabolize adenosine to inosine, did not alter transport of hexose into myocytes regardless of whether or not insulin was present. In contrast, PIA effectively inhibited 3-0-methyl-D-glucose uptake in myocytes even during insulin stimulation. PTA inhibited D-glucose-specific transport in both rat and bovine cardiac sarcolemmal vesicles (Ki=26 ,uM at [D-glucose] =5 mM). However, insulin did not affect glucose transport in sarcolemmal vesicles, which implies that receptorcoupled processes probably are not intact in this preparation. Thus, inhibition of PIA may not be receptor mediated. Also, PIA inhibited binding of cytochalasin B to bovine cardiac sarcolemmal vesicles, which supports the idea that PTA inhibits glucose flux by binding to the glucose transporter. To determine if adenosine altered glucose metabolism rather than transport, we measured the rate of 3H20 production from metabolism of D- [2 3H ]glucose in paced rat hearts ([D-glucose] =5.5 mM, [pyruvate] =0.2 mM) perfused with a range of PIA or adenosine concentrations with or without 0.01 ,uM insulin. Adenosine (0.01-100 1M) in the presence or absence of insulin increased coronary flow but did not change glycolytic rates. Similar results were obtained with PTA (no insulin) rather than adenosine in the perfusate. However, with glucose as the only exogenous substrate, 100 ,uM PTA inhibited glycolysis by approximately 50%. It also prevented hypoxia-induced increase in glycolysis in hearts perfused with glucose and pyruvate. We conclude that adenosine and PIA do not affect glycolysis in hearts perfused with pyruvate as an exogenous substrate but that PTA inhibits glucose utilization if glucose use is limited by membrane transport, such as with glucose as the sole exogenous substrate or during hypoxia. PTA Sanchez and Pina4 reported that adenosine produced insulinlike effects and enhanced glucose incorporation into epididymal fat pads. Subsequently, it was demonstrated that adenosine enhanced insulin-stimulated glucose transport,5-7 glucose metabolism,5-8 and antilipolysis9 in fat cells. However, disparate effects of adenosine have been found in skeletal muscle. Addition of adenosine deaminase to the incubation medium of soleus muscle strips'0 or extensor digitorum longus muscle prep- arations"1 increased the sensitivity of glycolysis to insulin. Furthermore, Budohoski et al'2 reported that the adenosine analogues 2-chloroadenosine and N6-(phenylisopropyl)adenosine decreased soleus muscle glycolysis sensitivity to insulin. Thus, adenosine attenuated (skeletal muscle) or enhanced (adipose tissue) the effects of insulin, depending on tissue type. However, the effects of adenosine or its derivatives on glucose utilization in the heart are not totally clear. For example, in perfused hearts, it has been reported that adenosine enhanced13 or had no effect in the absence of insulin1415 on glucose uptake.
In the latter studies, however, adenosine appeared to potentiate insulin-stimulated glucose uptake in perfused hearts.14'5 More recently, Wyatt et al16 reported that exogenous adenosine stimulated glycolytic flux in normoxic perfused rat hearts. They concluded that the effect of adenosine on glycolytic flux was mediated by interaction with A,-adenosine receptors. However, Shanahan et al17 reported that removal of adenosine by adenosine deaminase from the incubation medium of isolated rat cardiac myocytes did not affect insulin-stimulated 3 -O-methylglucose transport. We attempted to resolve these discrepancies and determine possible mechanisms of action of adenosine by ascertaining the effects of adenosine and the adenosine analogue N6-(L-2-phenylisopropyl)adenosine (PIA) on ally complete during passage through glycolysis and is a more sensitive measure of glucose utilization than glucose disappearance.26 3H20 was measured in samples of coronary effluent by adsorption of glucose onto Dowex-1 (borate form) in 8x20 mm columns27 and elution of 3H20 with three 0.5-ml aliquots of H20.
Radioactivity in the eluate was determined by liquid scintillation spectroscopy, and counts per minute were corrected for quench. Glycolytic flux was calculated from the rates of 3H20 production using the glucosespecific radioactivity of the heart perfusate and was expressed per gram dry heart weight.
Nucleoside Effects on Glucose Transport
Bovine cardiac sarcolemmal vesicles (2-4 mg protein/ml) were incubated with the various nucleoside analogues for 20 minutes (37°C) and then kept on ice until transport was determined. Rates of D-glucose and L-glucose flux (both 5 mM) into vesicles were quantified as described previously. [4-3H] CB in the buffers associated with the vesicle pellets. All incubations were in 160 mM NaCl, 20 mM MOPS-Tris, pH 7.4, and 5 ,uM cytochalasin E.
The binding reaction was terminated by centrifugation of vesicles through 0.7 ml silicone liquid (Dexter Hysol, Dow Corning). The supernatant fluid was aspirated, and the pelleted vesicles were suspended in Scintiverse E cocktail (Fisher Scientific Co., Pittsburgh, Pa.) for scintillation counting.
Statistics
To determine differences in hexose uptake into pretreated rat cardiac myocytes under the several conditions studied, the Kruskal-Wallis test followed by the Wilcoxon rank sum test were applied to the transport rates.28
Miscellaneous Assays and Reagents
Protein concentrations were determined using the Results
Glucose Transport
Preliminary experiments tested the hypothesis that adenosine increased glucose transport. This was done first with isolated myocytes in which 3-0-methyl-D-glucose uptake was determined during insulin-stimulated or control conditions in the presence or absence of adenosine. We found that adenosine concentrations as high as 100 ,tM did not affect hexose transport (data not shown). Subsequently, we measured 3-O-methyl-D-glucose uptake into myocytes after they were incubated with adenosine deaminase (1 unit/ml) or adenosine deaminase plus the nonmetabolizable adenosine analogue PIA (1 mM).
Adenosine deaminase was used to reduce cell-produced adenosine that may have masked the effects of added adenosine or PIA. PIA was used because in the initial adenosine studies, adenosine may have The results of these studies are illustrated in Figure  1 . rates gradually recovered partially, but even though nM) into vesicles were determined, and specific the hearts were electrically paced at the time samples ,lucose transport was calculated by subtracting nonwere taken to estimate glycolysis, reduced rates of [1-3H] 6 . Effects of N 6 (L-2-phenylisopropyl)adenosine (PL4) on coronary flow and glycolysis in perfused rat hearts. Rat hearts (n =6) were perfused with increasing concentrations of PL4 via the aorta with Krebs-Henseleit buffer as described in "Materials and Methods" at a pressure of 90 conditions. Hypothetically, elevated glycolysis would serve to protect the hypoxic heart, because with limited oxygen, more ATP can be produced by glucose oxidation than by fatty acid oxidation.
The conditions in which adenosine may increase glucose uptake in the heart appear to be dependent on the initial level of myocardial oxygen demand. 35 More precisely, the increase in glucose uptake subsequent to intracoronary adenosine infusion is amplified at higher initial myocardial oxygen requirements. Considering the findings of Jesmok et al,35 we expected to see increased glucose utilization in perfused hearts in the presence of adenosine at higher ventricular pressure (i.e., aortic perfusion pressure). However, regardless of the perfusion pressure in our experiments, adenosine (0.01-100 gM) with or without insulin does not affect glycolysis. Moreover, we find in myocytes that initial transport rates (which can be changed independent of metabolism) are not altered by adenosine.
ADO CONCENTRATION (uM) FIGURE 7. Effects of adenosine (ADO) on coronary flow and glycolysis in perfused rat hearts. Rat hearts (n=6) were perfused with increasing concentrations ofADO via the aorta with Krebs-Henseleit buffer as described in "Materials and Methods" at a pressure of 90 (panel A) or 125 (panel B) mm Hg. Perfusion pressure was adjusted to the appropriate level at each ADO dose 5 minutes before collection of coronary effluent sample; the sample was taken during the next 30 seconds, and the perfusate then was changed to one with the next higherADO concentration. Hearts were paced at 300 beats/min, andADO was removedfrom the perfusate after the 100 pM dose.
In contrast to our findings, Law and Raymond14 reported that adenosine potentiates insulin-stimulated myocardial glucose uptake in in vivo dog hearts.
Furthermore, Mainwaring et al13 found that adenosine infusion into perfused rat hearts increases glucose uptake directly in a manner similar to insulin. Later studies by Law et al15 disputed this, as they reported that adenosine has no effect in the absence of insulin. It is significant that these studies use differences in coronary arterial and venous glucose concentrations, and thus, conclusions regarding glucose utilization via the glycolytic pathway cannot be made.
To date, the only other study that considers the effects of adenosine on glycolytic flux in isolated perfused hearts is that of Wyatt et al. ' 6 These workers reported that adenosine stimulates glycolysis in both normoxic and hypoxic myocardium by interaction with A,-adenosine receptors, and they implicated a role for adenosine in physiological control of glucose utilization in the heart. These results conflict are at least two times the maintained flux during anoxia after depletion of glycogen.38 Thus, the absolute rates reported by Wyatt et al16 appear abnormally high.
Differences in the perfusion methods also may contribute to the disparate observations between the two studies. Hearts in the studies of Wyatt et al16 contained a saline-filled intraventricular balloon. We did not use a balloon in our experiments. Conceivably, adenosine-induced flow redistribution in hearts with higher diastolic pressure (i.e., hearts with balloons) could affect estimated glycolytic rates. However, we do not know of any studies that have evaluated carefully the effects of intraventricular balloons under a variety of conditions. We chose not to use balloons because of concern that they interfere with endocardial flow at low perfusion pressures and because oxygen consumption of the perfused rat heart without a balloon is directly proportional to the aortic perfusion pressure.39 From our experiments with high PIA concentrations, which show that PIA inhibits glycolysis or prevents its increase during hypoxia, it would be surprising if redistribution of flow would cause the PIA-induced increase in glycolysis observed by Wyatt et al. 16 Thus, we are at a loss to explain the discrepancies.
It is interesting that PIA inhibition of glucose utilization is observed only in hypoxic hearts and in aerobic hearts when glucose is the sole exogenous substrate. This is not unexpected if PIA is inhibiting transport, because under these two conditions, transport is rate limiting for glucose utilization,32 whereas with pyruvate in the perfusate, glycolysis would be controlled at phosphofructokinase.3640
PIA consistently inhibits hexose transport in isolated myocytes. This finding appears to be at odds with the data of Shanahan et al,17 who report that PIA alone does not affect basal transport of 3-0-methylglucose into isolated rat myocytes. However, their data are for PIA concentrations several hundred-fold lower than our estimate of Ki for PIA inhibition of methylglucose transport. Transport is inhibited only at the higher PIA concentrations.
The inhibitory action of PIA appears to occur by a noncompetitive mechanism at the glucose transport site and to be unrelated to its role as an adenosine (A1) receptor agonist for three reasons. First, PIA inhibits glucose transport in isolated purified sarcolemmal vesicles, and receptor-coupled mechanisms likely would be disrupted in this preparation. Indeed, we find that insulin does not stimulate glucose transport in sarcolemmal vesicle preparations, although insulin receptors are present as identified by 1251-insulin binding (unpublished data). Second, Martens et a'41 reported that PIA displaces binding of R-N6-_2'I-p-hydroxyphenylisopropyladenosine (an A,-selective radioligand) on rat ventricular myocyte membranes, with a Ki value of 0.2 nM. This value is much lower than the Ki (26 ,uM) we find for PIA inhibition of glucose transport into sarcolemmal vesicles. Thus, the effective PIA concentration for glucose transport inhibition is above that which would saturate all receptors, and the inhibition appears to be nonspecific. Finally, the observation that PIA displaces CB from its glucose-sensitive binding site further argues against receptor-mediated inhibition of glucose transport and indicates that PIA inhibits glucose transport by binding to the glucose transporter. This interaction between a nucleoside and the glucose transporter is not unprecedented. Jarvis and coworkers42 report that [ 'H]8-azidoadenosine can be used to photoaffinity label erythrocyte membrane band 4.5 polypeptides containing the glucose transporter. Its binding is inhibited by purine nucleosides, glucose, and CB but surprisingly not by PIA. This latter finding, along with the aforementioned different responses to PIA and adenosine in skeletal muscle and adipose tissues, suggests heterogeneity of the glucose transporter in different tissues. Thus, some of the purine molecules appear to interact with the glucose transporter in erythrocytes, and PIA (but not adenosine) does so in the heart.
